Ranger Investment Management L.P. Sells 4,955 Shares of Repligen Corporation $RGEN

Ranger Investment Management L.P. decreased its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 3.0% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 162,965 shares of the biotechnology company’s stock after selling 4,955 shares during the period. Ranger Investment Management L.P.’s holdings in Repligen were worth $21,784,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Brown Capital Management LLC raised its holdings in shares of Repligen by 16.3% in the 2nd quarter. Brown Capital Management LLC now owns 1,005,276 shares of the biotechnology company’s stock worth $125,036,000 after acquiring an additional 141,241 shares during the last quarter. Stephens Investment Management Group LLC raised its stake in shares of Repligen by 14.4% in the third quarter. Stephens Investment Management Group LLC now owns 598,356 shares of the biotechnology company’s stock worth $79,982,000 after purchasing an additional 75,509 shares during the last quarter. Geneva Capital Management LLC raised its stake in shares of Repligen by 239.6% in the second quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company’s stock worth $60,639,000 after purchasing an additional 343,991 shares during the last quarter. Thrivent Financial for Lutherans lifted its holdings in shares of Repligen by 6.7% in the third quarter. Thrivent Financial for Lutherans now owns 458,820 shares of the biotechnology company’s stock valued at $61,331,000 after purchasing an additional 28,716 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in shares of Repligen by 3,219.3% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company’s stock valued at $51,422,000 after buying an additional 400,970 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, COO James Bylund sold 2,191 shares of Repligen stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total transaction of $331,301.11. Following the completion of the sale, the chief operating officer owned 21,520 shares in the company, valued at approximately $3,254,039.20. This trade represents a 9.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Karen A. Dawes sold 275 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total transaction of $44,275.00. Following the completion of the transaction, the director owned 91,821 shares in the company, valued at approximately $14,783,181. This trade represents a 0.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 49,657 shares of company stock worth $7,721,077 in the last ninety days. 1.20% of the stock is currently owned by insiders.

Repligen Stock Down 1.6%

Repligen stock opened at $143.71 on Friday. The firm has a 50 day moving average price of $162.48 and a 200-day moving average price of $144.64. The company has a quick ratio of 7.14, a current ratio of 8.36 and a debt-to-equity ratio of 0.26. Repligen Corporation has a twelve month low of $102.96 and a twelve month high of $175.77. The company has a market capitalization of $8.09 billion, a P/E ratio of 7,209.90, a P/E/G ratio of 2.65 and a beta of 1.13.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. UBS Group increased their price target on Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Canaccord Genuity Group increased their target price on shares of Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a report on Wednesday, October 29th. Jefferies Financial Group set a $160.00 price target on shares of Repligen and gave the company a “hold” rating in a research report on Tuesday, October 28th. Barclays lifted their target price on shares of Repligen from $175.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Finally, Wall Street Zen lowered Repligen from a “buy” rating to a “hold” rating in a report on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $179.62.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.